Turn Therapeutics files Oct 6, 2026 investor presentation; exhibit text shows no financial or pipeline detail

Turn Therapeutics Inc.

Turn Therapeutics (Nasdaq: TTRX) furnished an updated corporate/investor presentation dated October 6, 2026 under Item 7.01 (Regulation FD).
Exhibit 99.1 as attached contains only the title line 'Corporate Presentation October 2026' — no revenue, cash, trial, pipeline, or guidance figures are present.
Filing signed October 6, 2026 by CEO Bradley Burnam; registrant address is 250 N. Westlake Blvd., Westlake Village, California 91362.
Because no substantive operating or financial data was disclosed, no directional read on the company's results is possible from this filing.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.